Standout Papers

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer 2014 2026 2018 2022 1.8k
  1. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014)
    Thomas Powles, Joseph P. Eder et al. Nature
  2. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma (2021)
    Thomas Powles, Jonathan E. Rosenberg et al. New England Journal of Medicine
  3. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study (2016)
    David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology
  4. The cancer-immunity cycle: Indication, genotype, and immunotype (2023)
    Ira Mellman, Daniel S. Chen et al. Immunity
  5. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial (2022)
    Thomas Powles, Kobe Yuen et al. Nature Medicine
  6. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up (2023)
    Thomas Powles, Se Hoon Park et al. Journal of Clinical Oncology
  7. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
    Jan Oldenburg, Daniel M. Berney et al. Annals of Oncology
  8. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) (2023)
    Thomas Powles, Begoña P. Valderrama et al. Annals of Oncology
  9. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma (2023)
    Jonathan E. Rosenberg, Thomas Powles et al. Annals of Oncology
  10. Renal cell carcinoma (2024)
    Matthew R. Young, Francesca Jackson‐Spence et al. The Lancet

Immediate Impact

18 by Nobel laureates 8 from Science/Nature 78 standout
Sub-graph 1 of 18

Citing Papers

Transformable Supramolecular Self‐Assembled Peptides for Cascade Self‐Enhanced Ferroptosis Primed Cancer Immunotherapy
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
11 intermediate papers

Works of Thomas Powles being referenced

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
2022 Standout
LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
2020
and 7 more

Author Peers

Author Last Decade Papers Cites
Thomas Powles 5003 5758 2754 333 10.0k
Yohann Loriot 4140 5998 4383 451 11.3k
Robert Dreicer 3731 3245 2875 179 8.1k
Andrea Necchi 8465 5560 2615 572 11.7k
Petros Grivas 4295 3804 1785 434 7.1k
Elizabeth R. Plimack 5664 7764 6099 315 13.6k
Jonathan E. Rosenberg 6703 5387 4043 399 13.0k
Jens Bedke 2693 2917 3748 311 7.3k
Matthew I. Milowsky 5240 3112 3427 271 9.9k
Daniel Castellano 3041 5179 3834 362 9.1k
Louis Lacombe 2654 3366 2898 176 7.0k

All Works

Loading papers...

Rankless by CCL
2026